Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Principal Accounting Officer | September 01, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date September 01, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,311 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 272 · Balance 66,311 F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026. F2: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026.
F2: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 4, 2026 20:25 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 272 | $5.53 | $1,504.16 |
DisclosureSEC source: 0001193125-26-383697 · ownership.xml · nonDerivative · entry 1 Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,311 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026. F2 · balance_after: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:31 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 265 | $4.43 | $1,173.95 |
DisclosureSEC source: 0001193125-26-253622 · ownership.xml · nonDerivative · entry 1 Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,583 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on May 29, 2026. F2 · balance_after: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,766 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:55 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 327 | $1.06 | $346.62 |
DisclosureSEC source: 0001193125-26-094490 · ownership.xml · nonDerivative · entry 1 Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,848 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on February 28, 2026. F2 · balance_after: Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,501 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:39 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 48,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-064166 · ownership.xml · nonDerivative · entry 1 Williams Sarah Joanne · CIK 0002108922 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,175 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F2 · balance_after: Includes the balance of (a) 10,938 RSUs which vest as follows: 1/4th of the RSUs vest in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (b) 11,850 RSUs which vest as follows: 1/16th of the RSUs vest in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,174 shares from the aggregate number of the RSUs issued under (a) and (b) above were sold to cover taxes and a total of 814 shares were sold on the open market. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.